Progress and challenges towards the development of malaria vaccines

BioDrugs

Volumn 21, Issue 6, 2007, Pages 357-373

  Tetteh, Kevin K A ^a   Polley, Spencer D ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Malaria vaccine, general; Research and development

Indexed keywords

ADENOVIRUS VECTOR; ALUMINUM POTASSIUM SULFATE; APICAL MEMBRANE ANTIGEN 1; ARTEMISININ; AS 02A; CHLOROQUINE; CIRSCUMSPOROZOITE PROTEIN; COMBINATION B ANTIGEN; DNA VACCINE; ERYTHROCYTE MEMBRANE PROTEIN 1; FANSIDAR; GLUTAMATE RICH PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; ICC 1132; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; ISA 51; LIVE VACCINE; LIVER STAGE ANTIGEN 1; LIVER STAGE ANTIGEN 3; MALARIA VACCINE; MEROZOITE SUFACE PROTEIN 1; MEROZOITE SUFACE PROTEIN 4; MEROZOITE SUFACE PROTEIN 5; MONTANIDE ISA 51; PARASITE ANTIGEN; PHOSPHORYL LIPID A; PNEUMOCOCCUS VACCINE; QS 21; RECOMBINANT HEPATITIS B VACCINE; REPEAT REGION T CELL EPITOPE AND HEPATITIS SURFACE ANTIGEN; SE 36; THROMBOSPONDIN RELATED ANONYMOUS PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADJUVANT THERAPY; ALLELE; ANTIBODY PRODUCTION; BED NET; CLINICAL TRIAL; DNA VECTOR; DRUG CONJUGATION; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; GENETIC ENGINEERING; GENOME; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; INFECTION PREVENTION; IRRADIATION; LICENSING; MALARIA; MUTAGENESIS; NONHUMAN; PARASITE IMMUNITY; PARASITE TRANSMISSION; PESTICIDE SPRAYING; PLASMODIUM FALCIPARUM; PLASMODIUM KNOWLESI; PLASMODIUM OVALE; PLASMODIUM VIVAX; PRIORITY JOURNAL; PRODUCTIVITY; PUBLIC HEALTH; REVIEW; RISK BENEFIT ANALYSIS; SPOROZOITE; STREPTOCOCCUS PNEUMONIAE; VACCINE PRODUCTION;

EID: 36348942862     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721060-00004     Document Type: Review

References (223)

1. Singh B, Kim Sung L, Matusop A, et al. A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet 2004 Mar 27; 363 (9414): 1017-24
2. Stoute JA, Heppner Jr DG, Mason CJ, et al. Phase 1 safety and immunogenicity trial of malaria vaccine RTS,S/AS02A in adults in a hyperendemic region of western Kenya. Am J Trop Med Hyg 2006 Jul; 75 (1): 166-70
3. Herrera S, Corradin G, Arévalo-Herrera M. An update on the search for a Plasmodium vivax vaccine. Trends Parasitol 2007 Mar; 23 (3): 122-8
4. Greenwood BM, Bojang K, Whitty CJ, et al. Malaria. Lancet 2005 Apr 23-29; 365 (9469): 1487-98
5. Sachs J, Malaney P. The economic and social burden of malaria. Nature 2002 Feb 7; 415 (6872): 680-5
6. Payne D. Spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today 1987 Aug; 3 (8): 241-6
7. Marsh K. Malaria disaster in Africa. Lancet 1998 Sep 19; 352 (9132): 924
8. Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997 Dec; 176 (6): 1590-6
9. Uhlemann AC, Cameron A, Eckstein-Ludwig U, et al. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol 2005 Jul; 12 (7): 628-9
10. Hemingway J, Bates I. Malaria: past problems and future prospects. After more than a decade of neglect, malaria is finally back on the agenda for both biomedical research and public health politics. EMBO Rep 2003 Jun; 4: S29-31
11. Smith S. A malaria vaccine: what if? ODI Opinions 2004; 17 [online]. Available from URL: http://www.odi.org.uk/Publications/opinions/17_immunisation- s_july04.html [Accessed 2007 Aug 27]
12. Moorthy VS, Good MF, Hill AV. Malaria vaccine developments. Lancet 2004 Jan 10; 363 (9403): 150-6
13. Berndt ER, Glennerster R, Kremer MR, et al. Advance market commitments for vaccines against neglected diseases: estimating costs and effectiveness. Health Econ 2007 May; 16 (5): 491-511
14. Hill AV. Pre-erythrocytic malaria vaccines: towards greater efficacy. Nat Rev Immunol 2006 Jan; 6 (1): 21-32
15. Nussenzweig RS, Vanderberg J, Spitalny GL, et al. Sporozoite-induced immunity in mammalian malaria: a review. Am J Trop Med Hyg 1972 Sep; 21 (5): 722-8
16. Hoffman SL, Goh LM, Luke TC, et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002 Apr 15; 185 (8): 1155-64
17. Egan JE, Hoffman SL, Haynes JD, et al. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 1993 Aug; 49 (2): 166-73
18. Carvalho LJ, Daniel-Ribeiro CT, Goto H. Malaria vaccine: candidate antigens, mechanisms, constraints and prospects. Scand J Immunol 2002 Oct; 56 (4): 327-43
19. Schofield L, Hewitt MC, Evans K, et al. Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature 2002 Aug 15; 418 (6899): 785-9
20. Herrington D, Davis J, Nardin E, et al. Successful immunization of humans with irradiated malaria sporozoites: humoral and cellular responses of the protected individuals. Am J Trop Med Hyg 1991 Nov; 45 (5): 539-47
21. Kumar KA, Sano G, Boscardin S, et al. The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 2006 Dec 14; 444 (7121): 937-40
22. Khusmith S, Charoenvit Y, Kumar S, et al. Protection against malaria by vaccination with sporozoite surface protein 2 plus CS protein. Science 1991 May 3; 252 (5006): 715-8
23. Zavala F, Cochrane AH, Nardin EH, et al. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med 1983 Jun 1; 157 (6): 1947-57
24. Marsh K, Kinyanjui S. Immune effector mechanisms in malaria. Parasite Immunol 2006 Jan-Feb; 28(1-2):51-60
25. Cohen S, Mc GI, Carrington S. Gamma-globulin and acquired immunity to human malaria. Nature 1961 Nov 25; 192: 733-7
26. Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991 Sep; 45 (3): 297-308
27. Flanagan KL, Plebanski M, Odhiambo K, et al. Cellular reactivity to the P. Falciparum protein trap in adult kenyans: novel epitopes, complex cytokine patterns, and the impact of natural antigenic variation. Am J Trop Med Hyg 2006 Mar; 74 (3): 367-75
28. Migot-Nabias F, Deloron P, Ringwald P, et al. Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. Trans R Soc Trop Med Hyg 2000 Sep-Oct; 94 (5): 557-62
29. Hammond GW, Parker J, Mimms L, et al. Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines. Vaccine 1991 Feb; 9 (2): 97-100
30. Dunachie SJ, Walther M, Epstein JE, et al. A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect Immun 2006 Oct; 74 (10): 5933-42
31. Moorthy VS, Imoukhuede EB, Milligan P, et al. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults. PLoS Med 2004 Nov; 1 (2): e33
32. Bejon P, Mwacharo J, Kai O, et al. A Phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials 2006 Oct 20; 1 (6): e29
33. Conway DJ, Polley SD. Measuring immune selection. Parasitology 2002; 125 Suppl.: S3-16
34. Deans JA, Alderson T, Thomas AW, et al. Rat monoclonal antibodies which inhibit the in vitro multiplication of Plasmodium knowlesi. Clin Exp Immunol 1982 Aug; 49 (2): 297-309
35. Polley SD, Mwangi T, Kocken CH, et al. Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine 2004 Dec 16; 23 (5): 718-28
36. Collins WE, Pye D, Crewther PE, et al. Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile. Am J Trop Med Hyg 1994 Dec; 51 (6): 711-9
37. Narum DL, Ogun SA, Thomas AW, et al. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun 2000 May; 68 (5): 2899-906
38. Calvo-Calle JM, Oliveira GA, Watta CO, et al. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge. Infect Immun 2006 Dec; 74 (12): 6929-39
39. Yoshida N, Nussenzweig RS, Potocnjak P, et al. Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science 1980 Jan 4; 207 (4426): 71-3
40. John CC, Moormann AM, Pregibon DC, et al. Correlation of high levels of antibodies to multiple pre-erythrocytic Plasmodium falciparum antigens and protection from infection. Am J Trop Med Hyg 2005 Jul; 73 (1): 222-8
41. Mlambo G, Mutambu SL, Mduluza T, et al. Antibody responses to Plasmodium falciparum vaccine candidate antigens in three areas distinct with respect to altitude. Acta Trop 2006 Nov; 100 (1-2): 70-8
42. Aley SB, Bates MD, Tam JP, et al. Synthetic peptides from the circumsporozoite proteins of Plasmodium falciparum and Plasmodium knowlesi recognize the human hepatoma cell line HepG2-A16 in vitro. J Exp Med 1986 Dec 1; 164 (6): 1915-22
43. Rogers WO, Rogers MD, Hedstrom RC, et al. Characterization of the gene encoding sporozoite surface protein 2, a protective Plasmodium yoelii sporozoite antigen. Mol Biochem Parasitol 1992 Jul; 53 (1-2): 45-51
44. Khusmith S, Sedegah M, Hoffman SL. Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2. Infect Immun 1994 Jul; 62 (7): 2979-83
45. John CC, Zickafoose JS, Sumba PO, et al. Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya. Infect Immun 2003 Aug; 71 (8): 4320-5
46. Dolo A, Modiano D, Doumbo O, et al. Thrombospondin related adhesive protein (TRAP), a potential malaria vaccine candidate. Parassitologia 1999 Sep; 41 (1-3): 425-8
47. Kurtis JD, Lanar DE, Opollo M, et al. Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. Infect Immun 1999 Jul; 67 (7): 3424-9
48. John CC, Moormann AM, Sumba PO, et al. Gamma interferon responses to Plasmodium falciparum liver-stage antigen 1 and thrombospondin-related adhesive protein and their relationship to age, transmission intensity, and protection against malaria. Infect Immun 2004 Sep; 72 (9): 5135-42
49. May J, Lell B, Luty AJ, et al. HLA-DQB1*0501-restricted Th1 type immune responses to Plasmodium falciparum liver stage antigen 1 protect against malaria anemia and reinfections. J Infect Dis 2001 Jan 1; 183 (1): 168-72
50. Brahimi K, Badell E, Sauzet JP, et al. Human antibodies against Plasmodium falciparum liver-stage antigen 3 cross-react with Plasmodium yoelii preerythrocytic-stage epitopes and inhibit sporozoite invasion in vitro and in vivo. Infect Immun 2001 Jun; 69 (6): 3845-52
51. Perlaza BL, Zapata C, Valencia AZ, et al. Immunogenicity and protective efficacy of Plasmodium falciparum liver-stage Ag-3 in Aotus lemurinus griseimembra monkeys. Eur J Immunol 2003 May; 33 (5): 1321-7
52. Daubersies P, Thomas AW, Millet P, et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3. Nat Med 2000 Nov; 6 (11): 1258-63
53. Meraldi V, Nebie I, Tiono AB, et al. Natural antibody response to Plasmodium falciparum Exp-1, MSP-3 and GLURP long synthetic peptides and association with protection. Parasite Immunol 2004 Jun-Jul; 26 (6-7): 265-72
54. Singh S, Miura K, Zhou H, et al. Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 2006 Aug; 74 (8): 4573-80
55. de Koning-Ward TF, O'Donnell RA, Drew DR, et al. A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. J Exp Med 2003 Sep 15; 198 (6): 869-75
56. Conway DJ, Cavanagh DR, Tanabe K, et al. A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med 2000 Jun; 6 (6): 689-92
57. Perraut R, Marrama L, Diouf B, et al. Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese village. J Infect Dis 2005 Jan 15; 191 (2): 264-71
58. Bergmann-Leitner ES, Duncan EH, Mullen GE, et al. Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. Am J Trop Med Hyg 2006 Sep; 75 (3): 437-42
59. Hui G, Hashimoto C. Plasmodium falciparum anti-MSP1-19 antibodies induced by MSP1-42 and MSP1-19 based vaccines differed in specificity and parasite growth inhibition in terms of recognition of conserved versus variant epitopes. Vaccine 2007 Jan 15; 25 (5): 948-56
60. Pan W, Huang D, Zhang Q, et al. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro. J Immunol 2004 May 15; 172 (10): 6167-74
61. Salazar LM, Alba MP, Torres MH, et al. Protection against experimental malaria associated with AMA-1 peptide analogue structures. FEBS Lett 2002 Sep 11; 527 (1-3): 95-100
62. Burns Jr JM, Flaherty PR, Nanavati P, et al. Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4. Infect Immun 2004 Oct; 72 (10): 5605-12
63. Cubillos M, Salazar LM, Torres L, et al. Protection against experimental P. falciparum malaria is associated with short AMA-1 peptide analogue alpha-helical structures. Biochimie 2002 Dec; 84 (12): 1181-8
64. Kocken CH, Withers-Martinez C, Dubbeld MA, et al. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infect Immun 2002 Aug; 70 (8): 4471-6
65. Stowers AW, Kennedy MC, Keegan BP, et al. Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria. Infect Immun 2002 Dec; 70 (12): 6961-7
66. Dutta S, Haynes JD, Moch JK, et al. Invasion-inhibitory antibodies inhibit proteolytic processing of apical membrane antigen 1 of Plasmodium falciparum merozoites. Proc Natl Acad Sci U S A 2003 Oct 14; 100 (21): 12295-300
67. Miao J, Li X, Liu Z, et al. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines. Vaccine 2006 Sep 11; 24 (37-39): 6187-98
68. Coley AM, Parisi K, Masciantonio R, et al. The most polymorphic residue on Plasmodium falciparum apical membrane antigen 1 determines binding of an invasion-inhibitory antibody. Infect Immun 2006 May; 74 (5): 2628-36
69. Healer J, Murphy V, Hodder AN, et al. Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol 2004 Apr; 52 (1): 159-68
70. Mullen GE, Giersing BK, Ajose-Popoola O, et al. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 2006 Mar 24; 24 (14): 2497-505
71. Sim BK, Narum DL, Liang H, et al. Induction of biologically active antibodies in mice, rabbits, and monkeys by Plasmodium falciparum EBA-175 region II DNA vaccine. Mol Med 2001 Apr; 7 (4): 247-54
72. Bermudez A, Cifuentes G, Guzman F, et al. Immunogenicity and protectivity of Plasmodium falciparum EBA-175 peptide and its analog is associated with alpha-helical region shortening and displacement. Biol Chem 2003 Oct-Nov; 384 (10-11): 1443-50
73. Jones TR, Narum DL, Gozalo AS, et al. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. J Infect Dis 2001 Jan 15; 183 (2): 303-12
74. Touŕe FS, Deloron P, Migot-Nabias F. Analysis of human antibodies to erythrocyte binding antigen 175 peptide 4 of Plasmodium falciparum. Clin Med Res 2006 Mar; 4 (1): 1-6
75. Pandey KC, Singh S, Pattnaik P, et al. Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Mol Biochem Parasitol 2002 Aug 7; 123 (1): 23-33
76. Singh AP, Puri SK, Chitnis CE. Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion. Mol Biochem Parasitol 2002 Apr 30; 121 (1): 21-31
77. Ridley RG, Takacs B, Etlinger H, et al. A rhoptry antigen of Plasmodium falciparum is protective in Saimiri monkeys. Parasitology 1990 Oct; 101 Pt 2: 187-92
78. Alifrangis M, Lemnge MM, Moon R, et al. IgG reactivities against recombinant Rhoptry-Associated Protein-1 (rRAP-1) are associated with mixed Plasmodium infections and protection against disease in Tanzanian children. Parasitology 1999 Oct; 119 (Pt 4): 337-42
79. Fonjungo PN, Elhassan IM, Cavanagh DR, et al. A longitudinal study of human antibody responses to Plasmodium falciparum rhoptry-associated protein 1 in a region of seasonal and unstable malaria transmission. Infect Immun 1999 Jun; 67 (6): 2975-85
80. Jacobson KC, Thurman J, Schmidt CM, et al. A study of antibody and T cell recognition of rhoptry-associated protein-1 (RAP-1) and RAP-2 recombinant proteins and peptides of Plasmodium falciparum in migrants and residents of the state of Rondonia, Brazil. Am J Trop Med Hyg 1998 Aug; 59 (2): 208-16
81. Stowers AW, Cooper JA, Ehrhardt T, et al. A peptide derived from a B cell epitope of Plasmodium falciparum rhoptry associated protein 2 specifically raises antibodies to rhoptry associated protein 1. Mol Biochem Parasitol 1996 Nov 25; 82 (2): 167-80
82. Harnyuttanakorn P, McBride JS, Donachie S, et al. Inhibitory monoclonal antibodies recognise epitopes adjacent to a proteolytic cleavage site on the RAP-1 protein of Plasmodium falciparum. Mol Biochem Parasitol 1992 Oct; 55 (1-2): 177-86
83. Perrin LH, Ramirez E, Lambert PH, et al. Inhibition of P. falciparum growth in human erythrocytes by monoclonal antibodies. Nature 1981 Jan 22; 289 (5795): 301-3
84. Howard RF, Jacobson KC, Rickel E, et al. Analysis of inhibitory epitopes in the Plasmodium falciparum rhoptry protein RAP-1 including identification of a second inhibitory epitope. Infect Immun 1998 Jan; 66 (1): 380-6
85. Okech B, Mujuzi G, Ogwal A, et al. High titers of IgG antibodies against Plasmodium falciparum serine repeat antigen 5 (SERA5) are associated with protection against severe malaria in Ugandan children. Am J Trop Med Hyg 2006 Feb; 74 (2): 191-7
86. Okech BA, Nalunkuma A, Okello D, et al. Natural human immunoglobulin G subclass responses to Plasmodium falciparum serine repeat antigen in Uganda. Am J Trop Med Hyg 2001 Dec; 65 (6): 912-7
87. Aoki S, Li J, Itagaki S, et al. Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth. J Biol Chem 2002 Dec 6; 277 (49): 47533-40
88. Fox BA, Horii T, Bzik DJ. Plasmodium falciparum: fine-mapping of an epitope of the serine repeat antigen that is a target of parasite-inhibitory antibodies. Exp Parasitol 2002 May; 101 (1): 69-72
89. Soe S, Singh S, Camus D, et al. Plasmodium falciparum serine repeat protein, a new target of monocyte-dependent antibody-mediated parasite killing. Infect Immun 2002 Dec; 70 (12): 7182-4
90. Metzger WG, Okenu DM, Cavanagh DR, et al. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol 2003 Jun; 25 (6): 307-12
91. Polley SD, Conway DJ, Cavanagh DR, et al. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. Vaccine 2006 May 8; 24 (19): 4233-46
92. Carvalho LJ, Oliveira SG, Theisen M, et al. Immunization of Saimiri sciureus monkeys with Plasmodium falciparum merozoite surface protein-3 and glutamate-rich protein suggests that protection is related to antibody levels. Scand J Immunol 2004 Apr; 59 (4): 363-72
93. Polley SD, Tetteh KK, Lloyd JM, et al. Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selection. J Infect Dis 2007 Jan 15; 195 (2): 279-87
94. Soe S, Theisen M, Roussilhon C, et al. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 2004 Jan; 72 (1): 247-52
95. Lundquist R, Nielsen LK, Jafarshad A, et al. Human recombinant antibodies against Plasmodium falciparum merozoite surface protein 3 cloned from peripheral blood leukocytes of individuals with immunity to malaria demonstrate antiparasitic properties. Infect Immun 2006 Jun; 74 (6): 3222-31
96. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, et al. Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 1994 Sep 1; 84 (5):1594-602
97. Goschnick MW, Black CG, Kedzierski L, et al. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. Infect Immun 2004 Oct; 72 (10): 5840-9
98. Kedzierski L, Black CG, Goschnick MW, et al. Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii. Infect Immun 2002 Dec; 70 (12): 6606-13
99. Kedzierski L, Black CG, Stowers AW, et al. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii. Vaccine 2001 Sep 14; 19 (32): 4661-8
100. Rainczuk A, Smooker PM, Kedzierski L, et al. The protective efficacy of MSP4/5 against lethal Plasmodium chabaudi adami challenge is dependent on the type of DNA vaccine vector and vaccination protocol. Vaccine 2003 Jun 20; 21 (21-22): 3030-42
101. Wang L, Richie TL, Stowers A, et al. Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam. Infect Immun 2001 Jul; 69 (7): 4390-7
102. Makobongo MO, Keegan B, Long CA, et al. Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 alpha protects against severe disease during Plasmodium falciparum reinfection. J Infect Dis 2006 Mar 1; 193 (5): 731-40
103. Moll K, Pettersson F, Vogt AM, et al. Generation of cross-protective antibodies against Plasmodium falciparum sequestration by immunization with an erythrocyte membrane protein 1-duffy binding-like 1{alpha} domain. Infect Immun 2007 Jan; 75 (1): 211-9
104. Ahuja S, Pettersson F, Moll K, et al. Induction of cross-reactive immune responses to NTS-DBL-1alpha/x of PfEMP1 and in vivo protection on challenge with Plasmodium falciparum. Vaccine 2006 Aug 28; 24 (35-36): 6140-54
105. Chen Q, Pettersson F, Vogt AM, et al. Immunization with PfEMP1-DBL1alpha generates antibodies that disrupt rosettes and protect against the sequestration of Plasmodium falciparum-infected erythrocytes. Vaccine 2004 Jul 29; 22 (21-22): 2701-12
106. Baruch DI, Gamain B, Barnwell JW, et al. Immunization of Aotus monkeys with a functional domain of the Plasmodium falciparum variant antigen induces protection against a lethal parasite line. Proc Natl Acad Sci U S A 2002 Mar 19; 99 (6): 3860-5
107. Joergensen L, Vestergaard LS, Turner L, et al. 3D7-derived plasmodium falciparum erythrocyte membrane protein 1 is a frequent target of naturally acquired antibodies recognizing protein domains in a particular pattern independent of malaria transmission intensity. J Immunol 2007 Jan 1; 178 (1): 428-35
108. Lusingu JP, Jensen AT, Vestergaard LS, et al. Levels of plasma immunoglobulin G with specificity against the cysteine-rich interdomain regions of a semicon-served Plasmodium falciparum erythrocyte membrane protein 1, VAR4, predict protection against malarial anemia and febrile episodes. Infect Immun 2006 May; 74 (5): 2867-75
109. Dodoo D, Staalsoe T, Giha H, et al. Antibodies to variant antigens on the surfaces of infected erythrocytes are associated with protection from malaria in Ghanaian children. Infect Immun 2001 Jun; 69 (6): 3713-8
110. Giha HA, Staalsoe T, Dodoo D, et al. Antibodies to variable Plasmodium falciparum-infected erythrocyte surface antigens are associated with protection from novel malaria infections. Immunol Lett 2000 Feb 1; 71 (2): 117-26
111. Avril M, Gamain B, Lepolard C, et al. Characterization of anti-var2CSA-PfEMP1 cytoadhesion inhibitory mouse monoclonal antibodies. Microbes Infect 2006 Nov-Dec; 8 (14-15): 2863-71
112. Yipp BG, Baruch DI, Brady C, et al. Recombinant PfEMP1 peptide inhibits and reverses cytoadherence of clinical Plasmodium falciparum isolates in vivo. Blood 2003 Jan 1; 101 (1): 331-7
113. Hogh B, Petersen E, Dziegiel M, et al. Antibodies to a recombinant glutamate-rich Plasmodium falciparum protein: evidence for protection of individuals living in a holoendemic area of Liberia. Am J Trop Med Hyg 1992 Mar; 46 (3): 307-13
114. Dziegiel M, Rowe P, Bennett S, et al. Immunoglobulin M and G antibody responses to Plasmodium falciparum glutamate-rich protein: correlation with clinical immunity in Gambian children. Infect Immun 1993 Jan; 61 (1): 103-8
115. Dodoo D, Theisen M, Kurtzhals JA, et al. Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 2000 Mar; 181 (3): 1202-5
116. Theisen M, Dodoo D, Toure-Balde A, et al. Selection of glutamate-rich protein long synthetic peptides for vaccine development: antigenicity and relationship with clinical protection and immunogenicity. Infect Immun 2001 Sep; 69 (9): 5223-9
117. Oeuvray C, Theisen M, Rogier C, et al. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 2000 May; 68 (5): 2617-20
118. Lusingu JP, Vestergaard LS, Alifrangis M, et al. Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission. Malar J 2005; 4: 48
119. Hermsen CC, Verhage DF, Telgt DS, et al. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine 2007 Apr 12; 25 (15): 2930-40
120. Theisen M, Soe S, Oeuvray C, et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 1998 Jan; 66 (1): 11-7
121. Theisen M, Soe S, Jessing SG, et al. Identification of a major B-cell epitope of the Plasmodium falciparum glutamate-rich protein (GLURP), targeted by human antibodies mediating parasite killing. Vaccine 2000 Sep 15; 19 (2-3): 204-12
122. Collins WE, Anders RF, Pappaioanou M, et al. Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature 1986 Sep 18-24; 323 (6085): 259-62
123. Collins WE, Pappaioanou M, Anders RF, et al. Immunization trials with the ring-infected erythrocyte surface antigen of Plasmodium falciparum in owl monkeys (Aotus vociferans). Am J Trop Med Hyg 1988 Mar; 38 (2): 268-82
124. Astagneau P, Chougnet C, Lepers JP, et al. Antibodies to the 4-mer repeat of the ring-infected erythrocyte surface antigen (Pf155/RESA) protect against Plasmodium falciparum malaria. Int J Epidemiol 1994 Feb; 23 (1): 169-75
125. al-Yaman F, Genton B, Anders R, et al. Assessment of the role of the humoral response to Plasmodium falciparum MSP2 compared to RESA and SPf66 in protecting Papua New Guinean children from clinical malaria. Parasite Immunol 1995 Sep; 17 (9): 493-501
126. Wahlin Flyg B, Siddique AB, Perlmann P, et al. Inhibition of in vitro growth of Plasmodium falciparum field isolates mediated by human antibodies to Pf155/ RESA and Pf332. Parasite Immunol 1999 Jun; 21 (6): 331-4
127. Siddique AB, Ahlborg N, Wahlin Flyg B, et al. Antibodies to sequences in a non-repeat region of Plasmodium falciparum antigen Pf155/RESA inhibit either cytoadherence or parasite growth in vitro. Parasitology 1998 Sep; 117 (Pt 3): 209-16
128. Roeffen W, Lensen T, Mulder B, et al. Transmission blocking immunity as observed in a feeder system and serological reactivity to Pfs 48/45 and Pfs230 differin field sera. Mem Inst Oswaldo Cruz 1994; 89 Suppl. 2: 13-5
129. Roeffen W, Mulder B, Teelen K, et al. Association between anti-Pfs48/45 reactivity and P. falciparum transmission-blocking activity in sera from Cameroon. Parasite Immunol 1996 Feb; 18 (2): 103-9
130. Drakeley CJ, Eling W, Teelen K, et al. Parasite infectivity and immunity to Plasmodium falciparum gametocytes in Gambian children. Parasite Immunol 2004 Apr; 26 (4): 159-65
131. Bustamante PJ, Woodruff DC, Oh J, et al. Differential ability of specific regions of Plasmodium falciparum sexual-stage antigen, Pfs230, to induce malaria transmission-blocking immunity. Parasite Immunol 2000 Aug; 22 (8): 373-80
132. Healer J, McGuinness D, Carter R, et al. Transmission-blocking immunity to Plasmodium falciparum in malaria-immune individuals is associated with antibodies to the gamete surface protein Pfs230. Parasitology 1999 Nov; 119 (Pt 5): 425-33
133. Healer J, McGuinness D, Hopcroft P, et al. Complement-mediated lysis of Plasmodium falciparum gametes by malaria-immune human sera is associated with antibodies to the gamete surface antigen Pfs230. Infect Immun 1997 Aug; 65 (8): 3017-23
134. Lobo CA, Dhar R, Kumar N. Immunization of mice with DNA-based Pfs25 elicits potent malaria transmission-blocking antibodies. Infect Immun 1999 Apr; 67 (4): 1688-93
135. Moelans II, Cohen J, Marchand M, et al. Induction of Plasmodium falciparum sporozoite-neutralizing antibodies upon vaccination with recombinant Pfs16 vaccinia virus and/or recombinant Pfs16 protein produced in yeast. Mol Biochem Parasitol 1995 Jun; 72 (1-2): 179-92
136. Arakawa T, Komesu A, Otsuki H, et al. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum. Infect Immun 2005 Nov; 73 (11): 7375-80
137. Kubler-Kielb J, Majadly F, Wu Y, et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci U S A 2007 Jan 2; 104 (1): 293-8
138. Ramjanee S, Robertson JS, Franke-Fayard B, et al. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine 2007 Jan 15; 25 (5): 886-94
139. Collins WE, Barnwell JW, Sullivan JS, et al. Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees. Am J Trop Med Hyg 2006 Feb; 74 (2): 215-21
140. Duffy PE, Kaslow DC. A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun 1997 Mar; 65 (3): 1109-13
141. McGregor IA. The passive transfer of human malarial immunity. Am J Trop Med Hyg 1964 Jan; 13 Suppl.: 237-9
142. Polley SD, Weedall GD, Thomas AW, et al. Orthologous gene sequences of merozoite surface protein 1 (MSP1) from Plasmodium reichenowi and P. gallinaceum confirm an ancient divergence of P. falciparum alleles. Mol Biochem Parasitol 2005 Jul; 142 (1): 25-31
143. Adams JH, Sim BK, Dolan SA, et al. A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A 1992 Aug 1; 89 (15): 7085-9
144. Chatterjee S, Perignon JL, Van Marck E, et al. How reliable are models for malaria vaccine development? Lessons from irradiated sporozoite immunizations. J Postgrad Med 2006 Oct-Dec; 52 (4): 321-4
145. Singh S, Soe S, Mejia JP, et al. Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies to improve vaccine design. J Infect Dis 2004 Sep 1; 190 (5): 1010-8
146. Herrera S, Herrera MA, Perlaza BL, et al. Immunization of Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins. Proc Natl Acad Sci U S A 1990 May; 87 (10): 4017-21
147. Gramzinski RA, Obaldia 3rd N, Jones TR, et al. Susceptibility of Panamanian Aotus lemurinus lemurinus to sporozoite-induced Plasmodium falciparum (Santa Lucia) infection. Am J Trop Med Hyg 1999 Jul; 61 (1): 19-25
148. Miller LH, Haynes JD, McAuliffe FM, et al. Evidence for deifferences in erythrocyte surface receptors for the malaria parasites Plasmodium falciparum and Plasmodium knowlesi. J Exp Med 1977; 46: 277-81
149. Martin MJ, Rayner JC, Gagneux P, et al. Evolution of human-chimpanzee differences in malaria susceptibility: relationship to human genetic loss of N-glycolylneuraminic acid. Proc Natl Acad Sci U S A 2005 Sep 6; 102 (36): 12819-24
150. Malaria vaccine technology roadmap [online]. Available from URL: http://www.malariavaccineroadmap.net/ [Accessed 2007 Aug 27]
151. Supporting development of a vaccine for malaria, the deadliest disease among Africa's children [online]. Available from URL: http://www. gatesfoundation.org/nr/downloads/aboutus/learning/mvi.pdf [Accessed 2007 Aug 27]
152. Malaria Vaccine Initiative. Clinical trials: crucial steps on the road to a malaria vaccine [technical series]. 2004 Aug [online]. Available from URL: http://www.malariavaccineroadmap.net/pdfs/vaccine_steps.pdf [Accessed 2007 Aug 27]
153. Webster DP, Dunachie S, Vuola JM, et al. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 2005 Mar 29; 102 (13): 4836-41
154. Day KP, Karamalis F, Thompson J, et al. Genes necessary for expression of a virulence determinant and for transmission of Plasmodium falciparum are located on a 0.3-megabase region of chromosome 9. Proc Natl Acad Sci U S A 1993 Sep 1; 90 (17): 8292-6
155. Pologe LG, Ravetch JV. A chromosomal rearrangement in a P. falciparum histidine-rich protein gene is associated with the knobless phenotype. Nature 1986 Jul 31-Aug 6; 322 (6078): 474-7
156. Haiti: scaling the mountains. AIDS vaccine trial begins in the western hemisphere's hardest-hit country [online]. Available from URL: http://www.aegis.com/pubs/iavi/2001/IAVI2001-0404.html [Accessed 2007 Aug 27]
157. Maar M, McGregor-Sutherland M, McGregor L. First nations taking charge of health research: the development of a community-based ethics review process on Manitoulin Island, Ontario, Canada. A report prepared for the National Council for Ethics in Human Research (NCEHR) [online]. Available from URL: http://www.ncehr-cnerh.org/pdf/whats_new/manitoulin_report_march_2005_english. pdf [Accessed 2007 Aug 27]
158. Stoute JA, Slaoui M, Heppner DG, et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997 Jan 9; 336 (2): 86-91
159. Gupta RK, Siber GR. Adjuvants for human vaccines: current status, problems and future prospects. Vaccine 1995 Oct; 13 (14): 1263-76
160. World Health Organization. New vaccines against infectious diseases: research and development status IVR. April 2005, updated February 2006 [online]. Available from URL: http://www.who.int/vaccine_research/documents/en/Status_T- able.pdf [Accessed 2007 Aug 27]
161. Alonso PL, Sacarlal J, Aponte JJ, et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 2005 Dec 10; 366 (9502): 2012-8
162. Bojang KA, Olodude F, Pinder M, et al. Safety and immunogenicty of RTS,S/ AS02A candidate malaria vaccine in Gambian children. Vaccine 2005 Jul 14; 23 (32): 4148-57
163. Macete E, Aponte JJ, Guinovart C, et al. Safety and immunogenicity of the RTS,S/ AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. Trop Med Int Health 2007 Jan; 12 (1): 37-46
164. Stoute JA, Kester KE, Krzych U, et al. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 1998 Oct; 178 (4): 1139-44
165. Doherty JF, Pinder M, Tornieporth N, et al. A phase I safety and immunogenicity trial with the candidate malaria vaccine RTS,S/SBAS2 in semi-immune adults in The Gambia. Am J Trop Med Hyg 1999 Dec; 61 (6): 865-8
166. Bojang KA, Milligan PJ, Pinder M, et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001 Dec 8; 358 (9297): 1927-34
167. Lopez JA, Weilenman C, Audran R, et al. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. implications for vaccination strategies. Eur J Immunol 2001 Jul; 31 (7): 1989-98
168. Meraldi V, Audran R, Romero JF, et al. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine 2003 Jun 2; 21 (19-20): 2485-91
169. Nardin EH, Oliveira GA, Calvo-Calle JM, et al. Phase I testing of a malaria vaccine composed of hepatitis B virus core particles expressing Plasmodium falciparum circumsporozoite epitopes. Infect Immun 2004 Nov; 72 (11): 6519-27
170. Walther M, Dunachie S, Keating S, et al. Safety, immunogenicity and efficacy of a pre-erythrocytic malaria candidate vaccine, ICC-1132 formulated in Seppic ISA 720. Vaccine 2005 Jan 4; 23 (7): 857-64
171. Oliveira GA, Wetzel K, Calvo-Calle JM, et al. Safety and enhanced immunogenicity of a hepatitis B core particle Plasmodium falciparum malaria vaccine formulated in adjuvant Montanide ISA 720 in a phase I trial. Infect Immun 2005 Jun; 73 (6): 3587-97
172. Parker SE, Monteith D, Horton H, et al. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene Ther 2001 Jul; 8 (13): 1011-23
173. Hillier CJ, Ware LA, Barbosa A, et al. Process development and analysis of liver-stage antigen 1, a preerythrocyte-stage protein-based vaccine for Plasmodium falciparum. Infect Immun 2005 Apr; 73 (4): 2109-15
174. Moorthy VS, Pinder M, Reece WH, et al. Safety and immunogenicity of DNA/ modified vaccinia virus Ankara malaria vaccination in African adults. J Infect Dis 2003 Oct 15; 188 (8): 1239-44
175. Moorthy VS, Imoukhuede EB, Keating S, et al. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J Infect Dis 2004 Jun 15; 189 (12): 2213-9
176. Bejon P, Mwacharo J, Kai OK, et al. Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1-6 year old children in a malaria endemic area. Vaccine 2006 May 29; 24 (22): 4709-15
177. Ophorst OJ, Radosevic K, Havenga MJ, et al. Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice. Infect Immun 2006 Jan; 74 (1): 313-20
178. Bejon P, Andrews L, Andersen RF, et al. Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. J Infect Dis 2005 Feb 15; 191 (4): 619-26
179. BenMohamed L, Gras-Masse H, Tartar A, et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur J Immunol 1997 May; 27 (5): 1242-53
180. Pattnaik P, Shakri AR, Singh S, et al. Immunogenicity of a recombinant malaria vaccine based on receptor binding domain of Plasmodium falciparum EBA-175. Vaccine 2007 Jan 15; 25 (5): 806-13
181. Ockenhouse CF, Angov E, Kester KE, et al. Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine 2006 Apr 5; 24 (15): 3009-17
182. Langermans JA, Hensmann M, van Gijlswijk M, et al. Preclinical evaluation of a chimeric malaria vaccine candidate in montanide ISA 720: immunogenicity and safety in rhesus macaques. Hum Vaccin 2006 Sep 11; 2 (5): 222-6
183. Qian F, Pan W. Construction of a tetR-integrated Salmonella enterica serovar Typhi CVD908 strain that tightly controls expression of the major merozoite surface protein of Plasmodium falciparum for applications in human vaccine production. Infect Immun 2002 Apr; 70 (4): 2029-38
184. Toebe CS, Clements JD, Cardenas L, et al. Evaluation of immunogenicity of an oral Salmonella vaccine expressing recombinant Plasmodium berghei merozoite surface protein-1. Am J Trop Med Hyg 1997 Feb; 56 (2): 192-9
185. Matsumoto S, Yukitake H, Kanbara H, et al. Recombinant Mycobacterium bovis bacillus Calmette-Guerin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies. J Exp Med 1998 Sep 7; 188 (5): 845-54
186. Matsumoto S, Yukitake H, Kanbara H, et al. Long-lasting protective immunity against rodent malaria parasite infection at the blood stage by recombinant BCG secreting merozoite surface protein-1. Vaccine 1999 Dec 10; 18 (9-10): 832-4
187. Audran R, Cachat M, Lurati F, et al. Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 2005 Dec; 73 (12): 8017-26
188. Theisen M, Soe S, Brunstedt K, et al. A Plasmodium falciparum GLURP-MSP3 chimeric protein: expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine 2004 Mar 12; 22 (9-10): 1188-98
189. Carvalho LJ, Alves FA, Bianco Jr C, et al. Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide ISA720 adjuvants. Clin Diagn Lab Immunol 2005 Feb; 12 (2): 242-8
190. Genton B, Betuela I, Felger I, et al. A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea. J Infect Dis 2002 Mar 15; 185 (6): 820-7
191. Genton B, Al-Yaman F, Betuela I, et al. Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine 2003 Dec 8; 22 (1): 30-41
192. Arizono N, Nakanihsi K, Horii T, et al. Progress in the molecular biology of malaria and the immunology of nematode infections. Trends Parasitol 2007 Apr; 23 (4): 175-81
193. Zou L, Miles AP, Wang J, et al. Expression of malaria transmission-blocking vaccine antigen Pfs25 in Pichia pastoris for use in human clinical trials. Vaccine 2003 Apr 2; 21 (15): 1650-7
194. Wu Y, Przysiecki C, Flanagan E, et al. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Proc Natl Acad Sci U S A 2006 Nov 28; 103 (48): 18243-8
195. Acosta CJ, Galindo CM, Schellenberg D, et al. Evaluation of the SPf66 vaccine for malaria control when delivered through the EPI scheme in Tanzania. Trop Med Int Health 1999 May; 4 (5): 368-76
196. Alonso PL, Sacarlal J, Aponte JJ, et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004 Oct 16-22; 364 (9443): 1411-20
197. Good MF, Pombo D, Quakyi IA, et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci U S A 1988 Feb; 85 (4): 1199-203
198. Taylor RR, Smith DB, Robinson VJ, et al. Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun 1995 Nov; 63 (11): 4382-8
199. Tetteh KK, Cavanagh DR, Corran P, et al. Extensive antigenic polymorphism within the repeat sequence of the Plasmodium falciparum merozoite surface protein 1 block 2 is incorporated in a minimal polyvalent immunogen. Infect Immun 2005 Sep; 73 (9): 5928-35
200. Polley SD, Tetteh KK, Cavanagh DR, et al. Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria. Infect Immun 2003 Apr; 71 (4): 1833-42
201. Franks S, Baton L, Tetteh K, et al. Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun 2003 Jun; 71 (6): 3485-95
202. McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005 Oct 15; 41 (8): 1114-22
203. Enosse S, Dobano C, Quelhas D, et al. RTS,S/AS02A Malaria vaccine does not induce parasite CSP T cell epitope selection and reduces multiplicity of infection. PLoS Clin Trials 2006 May; 1 (1): e5
204. Druilhe P, Spertini F, Soesoe D, et al. A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2005 Nov; 2 (11): e344
205. Croteau G, Doyon L, Thibeault D, et al. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 1997 Feb; 71 (2): 1089-96
206. van Dijk MR, Douradinha B, Franke-Fayard B, et al. Genetically attenuated, P36p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci U S A 2005 Aug 23; 102 (34): 12194-9
207. Mueller AK, Labaied M, Kappe SH, et al. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005 Jan 13; 433 (7022): 164-7
208. Good MF. Genetically modified Plasmodium highlights the potential of whole parasite vaccine strategies. Trends Immunol 2005 Jun; 26 (6): 295-7
209. Butler D. Mosquito production mooted as fast track to malaria vaccine. Nature 2003 Oct 2; 425 (6957): 437
210. Gardner MJ, Hall N, Fung E, et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature 2002 Oct 3; 419 (6906): 498-511
211. Hall N, Karras M, Raine JD, et al. A comprehensive survey of the Plasmodium life cycle by genomic, transcriptomic, and proteomic analyses. Science 2005 Jan 7; 307 (5706): 82-6
212. Fraunholz MJ. Systems biology in malaria research. Trends Parasitol 2005 Sep; 21 (9): 393-5
213. Ecker A, Moon R, Sinden RE, et al. Generation of gene targeting constructs for Plasmodium berghei by a PCR-based method amenable to high throughput applications. Mol Biochem Parasitol 2006 Feb; 145 (2): 265-8
214. Duraisingh MT, Triglia T, Cowman AF. Negative selection of Plasmodium falciparum reveals targeted gene deletion by double crossover recombination. Int J Parasitol 2002 Jan; 32 (1): 81-9
215. Cowman AF, Crabb BS. Invasion of red blood cells by malaria parasites. Cell 2006 Feb 24; 124 (4): 755-66
216. Cooke BM, Buckingham DW, Glenister FK, et al. A Maurer's cleft-associated protein is essential for expression of the major malaria virulence antigen on the surface of infected red blood cells. J Cell Biol 2006 Mar 13; 172 (6): 899-908
217. Rug M, Prescott SW, Fernandez KM, et al. The role of KAHRP domains in knob formation and cytoadherence of P. falciparum-infected human erythrocytes. Blood 2006 Jul 1; 108 (1): 370-8
218. Crabb BS, Cooke BM, Reeder JC, et al. Targeted gene disruption shows that knobs enable malaria-infected red cells to cytoadhere under physiological shear stress. Cell 1997 Apr 18; 89 (2): 287-96
219. Balu B, Shoue DA, Fraser Jr MJ, et al. High-efficiency transformation of Plasmodium falciparum by the lepidopteran transposable element piggyBac. Proc Natl Acad Sci U S A. 2005 Nov 8; 102 (45): 16391-6
220. Nkrumah LJ, Muhle RA, Moura PA, et al. Efficient site-specific integration in Plasmodium falciparum chromosomes mediated by mycobacteriophage Bxb1 integrase. Nat Methods 2006 Aug; 3 (8): 615-21
221. Crabb BS, Gilson PR. A new system for rapid plasmid integration in Plasmodium parasites. Trends Microbiol 2007 Jan; 15 (1): 3-6
222. Meissner M, Krejany E, Gilson PR, et al. Tetracycline analogue-regulated transgene expression in Plasmodium falciparum blood stages using Toxoplasma gondii transactivators. Proc Natl Acad Sci U S A 2005 Feb 22; 102 (8): 2980-5
223. Tediosi F, Hutton G, Maire N, et al. Predicting the cost-effectiveness of introducing a pre-erythrocytic malaria vaccine into the expanded program on immunization in Tanzania. Am J Trop Med Hyg 2006 Aug; 75 (2 Suppl.): 131-43